REFERENCES
1. A P Boon et al : 10 years review of invasive aspergillosis detected
at narcolepsy, J clin pathol 1991, 44, 452-454
2. A.Haugaard et al: early chest radiography and CT in the diagnosis
,management and out come of invasive pulmonary aspergillosis acta radiologica
43, (2002) 292-298
3. A.H.Groll et al: five -years-survey of invasive aspergillosis in
a pediatric cancer centre. Epidemiology, management and long term survival,
mycosis 42, 431-442 (1999)
4. Andrea Hayes-Jordan et al: open lung biopsy in pediatric bone marrow
transplant patients; Journal of pediatric surgery, vol 37, no 3 (March)
2002: pp 446-452
5. Caillot D: improved management of IPA in neutropenic patients using
early thoracic CT and surgery, J of clinical oncology, 15:139, 1997
6. Christopher T.Salerno et al: surgical therapy for pulmonary aspergillosis
in immunocompromised patients Ann Thorac surg 1998, 65, 1415-9
7. Clare Savage et al: hemoptysis secondary to pulmonary pseudoaneurysm
30 years after a gunshot wound, Ann thorac surg 2001, 71, 1021-3
8. David W. Denning et al: efficacy and safety of voriconazole in the
treatment of acute invasive asergillosis, clinical infectious diseases
2002, 34, 563-571
9. Dominique Gossot et al: full thoracoscopic approach for surgical
management of invasive pulmonary aspergillosis, Ann Thorac Surg 2002,73,
240-4
10. Dieter Buchheidt et al: clinical evaluation of PCR assay to detect
Aspergillus species in bronchoalveolar lavage samples of neutropenic
patients.
11. Eddy Jean-Baptiste : clinical assessment and management of massive
haemoptysis, crit. Care med 2000, vol 28, p.1642-47
12. Erik J .Dubach et al :burden of aspergillosis -related hospitalizations
in the united states clinical infectious disease 2000; 1524-8
13. Frank Reichenberger et al: lung resection for invasive pulmonary
aspergillosis in neutropenic patients with hematological diseases Ann
J respir crit care med vol 158, pp885-890,1998
14. F Reichenberger et al: diagnostic yield of bronchoscopy in histologically
proven invasive pulmonary aspergillosis; bone marrow transplantation
(1999) 24 .1195-1199
15. G.F.Behre et al: Aerosol amphotercin B inhalations for prevention
of invasive pulmonary aspergillosis in neutropenic cancer patients Ann
hematol (1995), 71, 287-291
16. G.Todeschini C .Murari et al: invasive aspergillosis in neutropnic
patients : rapid neutrophil recovery is a risk factor for sever pulmonary
complication European Journal of clinical investigation (1999) 29, 453-457
17. Gorelik et al: fatal hemoptysis induced by invasive pulmonary aspergillosis
in patients with acute leukemia buring bone marrow and clinical remission:
reports of two cases and review of the literature, 2000, the British
infectionj society
18. Hans J Dornbusch et al: treatment of invasive pulmonary aspergillosis
in severely neutropenic children with malignant disorder using ambisone
and GCSF pediatric hematology and oncology 12(6) 577-586,1995
19. Hyung Jin Won et al: invasive pulmonary aspergillosis : prediction
at thin - section CT patients with Neutropenia - A prospective study,
radiology 1998; 208:777-782
20. Issam Raad et al : PCR on blood for the diagnosis of invasive pulmonary
aspergillosis in cancer patients, cancer, February 15, 2002, vol 94/number
4
21. James M.Habicht at al: invasive fungal infection in hematologic
patients: is resection effective? the hematology journal 2001, 2, 250-256
22. J. Cap et al: fluconazole in children, chemotherapy 1993, 39, 438-442
23. Jean-Francois Regnard et al: A series of 89 surgical cases Ann Thorac
Surg 2000, 69, 898-903
24. J.L.Harousseau et al: Itraconazole oral solution for treatment for
primary prophylaxis for fungal infection inpatients with hematological
malignancy and profound neutropenia Antimicrobial agents and chemotherapy,
July, 2000,p.1887-1893
25. J.J.W.M.Janssen et al: out come of ICU treatment in invasive aspergillosis
;intensive care med (1996) 222, 1325-1322
26. John R Perfect at al: voriconazole treatment for less-common,emerging,or
refractory fungal infections, clinical inf. Diseases 2003, 36, 1122-31
27. Livio Panago et al : the role of bronchoalveolar lavage in the microbiological
diagnosis of pneumonia in patients with haematological diseases, Ann
med 29 535-540.
28. Masahirno Kami et al: use of real -time PCR on blood samples for
diagnosis of invasive aspergillosis clinical infectious diseases 2001,33:1504-1512
29. Mashiro Kami et al: computed tomography of the chest, latex agglutination
test and plasma 1-3)_-D-glucan assay in early diagnosis of invasive
aspergillosis, Haematologica 2000; 85:745-752
30. Marcio Nucci et al: double, blinded ,randomized placebo-controlled
trial of itraconazole capsules as anti fungal prophylaxis for neutropenic
patients, clinical infectious diseases 2000, 30, 300-5
31. Mary H. White et al: Amphotercin B colloidal dispersion VS amphotercin
B as therapy for invasive aspergillosis clinical infectious diseases
1997; 24, 635-642
32. M. Von.Eiff et al pulmonary aspergillosis: early diagnosis improve
survival; respiration 1995, 62, 341-347
33. M. Cornet et al : epidemiology of invasive aspergillosis in France
J of hospital infection ,2002, 51, 288-296
34. M E Ellis et al : progressive chronic pulmonary aspergillosis, J
of the royal society of medicine vol 85, December 1992 p.763-4
35. M. Karim et al : chronic invasive aspergillosis in apparently immunocomptent
hosts, clin infect dis 1997, 24, 723-33
36. Min Joo Kim et al: crescent sign in invasive pulmonary aspergillosis:
frequency and related CT and clinical factors Journal of computer assisted
tomography 25:305-310.
37. M E Jones et al PCR-ELISA for the early diagnosis of invasive pulmonary
asergillus infection in neutropenic patients; J clin pathol 1998; 51,
652-656
38. O.Rinden et al: efficacy of amphotercin B encapsulated in liposome
(ambisone) in the treatment of invasive fungal infections in the treatment
of invasive fungal infection in immunocompromised patients Journal of
antimicrobial chemotherapy (1991) 28, suppl.B.73-82
39. O.Rigden and J.Tollemar: liposomal amphotercin B ( ambisone) treatment
of invasive fungal infection in immunocompromised children , mycosis
,36,187-192 (1993)
40. Patterson, Thomas F: disease spectrum, treatment practice and outcome,
medicine (Baltimore), vol79, July, 2000. 250-260
41. Paul Pianosi and H Al-sadoon: hemoptysis in children, pediatric
in review vol 17, no.10, oct 96.
42. Raleigh Bowden et al: A double blind, controlled trial of Amphotercin
B colloidal dispersion versus Amphotercin B for treatment of invasive
aspergillosis in immunocompromised patients
43. Raed A Dweik et al: role of bronchoscopy in massive haemoptysis,
clinics in chest medicine, vol 20, number 1, march 1999.
44. Raoul Herbrecht et al : voriconazole versus amphotercin B for primary
treatment of invasive aspergillosis N Eng J Med vol 347, no.6 (august
8 ) 2002
45. Stanley C. Deresinski and David A Stevens: caspofungin clinical
infec. Diseases ,2003, 1445-57
46. Seema Abbasi et al, apergillosis in children with cancer : a 34
years experience, clinical infectious diseases 1999; 29: 1210-9.
47. Sharon Walmsley et al : invasive aspergillosis in a pediatric hospital,
J of infect dis, 1993, 12, 673-82
48. S.Bretagne et al :serum aspergillus galactomannan antigen testing
by sandwish ELISA: practical use in neutropenic patients Journal of
infection (1997), 35, 7-15
49. Swu-Jane Lin et al: aspergillosis case fatality rate, clinic infect
dis 2001, 32, 358-66
50. Timothy B. Allff et al: refractory aspergillus pneumonia in patients
with acute leukemia, cancer February 15, 2003 vol 97, number 4
51. Thomas J. Walsh et al :voriconazole in the treatment of aspergillosis
,pediatric infectious diseases journal .2002, 21:240-8
52. T.J. Marchall et al : the role of radiology in the investigations
and managements of patients with hemoptysis, 1996, the royal college
of radiologist, clinical radiology, 51,391-400
53. V. Ribrag et al : prognostic factors for invasive pulmonary aspergillosis
in leukemic patients, J of leukemia and lymphoma vol. 10, pp.317-321
12 15
THANK YOU FOR JOINING US FOR THE CROSS-CANADA PAEDIATRIC RESPIRATORY ROUNDS. HOPE TO SEE YOU NEXT TIME.Thank you to AstraZeneca for their support of this program and website.
BACK TO HOME